Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 3/20 | 0.57 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | ROR1 | Q01973 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22465759 | 0.87 | CACNA1H (0.62) | CACNA1HELANEABCB1ABCG2KDM4E | |
| SCHEMBL22465371 | 0.86 | CACNA1H (0.51) | CACNA1HROR1ABCB1ABCG2CYP19A1 | |
| SCHEMBL22465621 | 0.83 | CACNA1H (0.77) | CACNA1HABCG2 | |
| SCHEMBL22465740 | 0.81 | KDM4E (0.49) | CACNA1HROR1ABCG2KDM4EALDH1A1 | |
| SCHEMBL29927617 | 0.77 | CACNA1H (0.76) | CACNA1HCYP19A1PDCD1CD274 | |
| SCHEMBL22465354 | 0.77 | CACNA1H (0.76) | CACNA1HCYP19A1PDCD1CD274 | |
| SCHEMBL22465742 | 0.76 | PDCD1 (0.50) | CACNA1HELANEROR1ABCB1ABCG2 | |
| SCHEMBL22465359 | 0.76 | ROR1 (0.61) | ROR1ABCG2KDM4EALDH1A1HPGD | |
| SCHEMBL22465242 | 0.74 | CACNA1H (0.54) | CACNA1HABCB1ABCG2PDCD1CD274 | |
| SCHEMBL22465607 | 0.73 | CACNA1H (1.00) | CACNA1HCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11479537-B2 | T-type calcium channel inhibitor | KINKI UNIVERSITY (JP) | 2022-10-25 | — | — | US | disclosed |
| US-20200308132-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479537-B2 | T-type calcium channel inhibitor | CACNA1H, CACNA1I, CACNA1G | CACNA1H 1/4885ELANE 4725/4885ROR1 1712/4885 |
| US-20200308132-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1H, CACNA1I, CACNA1G | CACNA1H 1/4885ELANE 4725/4885ROR1 1712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.